Emicizumab‑Kxwh Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL
Reference Brands: Hemlibra (USA/EU)
Category: Plasma Products
Emicizumab-kxwh is a humanized bispecific monoclonal antibody (IgG4) that simultaneously binds activated factor IX (FIXa) and factor X (FX), thereby functioning as a factor VIII cofactor‐mimetic in patients with congenital haemophilia A. It is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A, with or without factor VIII inhibitors. It offers subcutaneous administration (once weekly, biweekly or every 4 weeks) compared to more frequent intravenous factor VIII infusions.
Emicizumab‑Kxwh — third party manufacturing & bulk supply
Emicizumab‑Kxwh is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Emicizumab‑Kxwh listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Emicizumab‑Kxwh →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Emicizumab-kxwh is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. It helps restore the function of missing activated factor VIII, thereby improving blood clotting.
Emicizumab-kxwh is made from a recombinant humanized monoclonal antibody. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
The trade name of Emicizumab-kxwh is Hemlibra.
Emicizumab-kxwh is manufactured by Genentech, a member of the Roche Group.
The generic name of this product is Emicizumab-kxwh.
The brand name is Hemlibra.
Emicizumab-kxwh (Hemlibra) is manufactured by Genentech, Inc., South San Francisco, California, USA, and also produced at Roche facilities in Japan and Switzerland.
Related Products
Marstacimab‑Hncq
Strength:
150 mg/mL
Form: injection (prefilled syringe)
Reference Brands: Hympavzi (USA)
View Details
Concizumab-Mtci
Strength:
60 mg/1.5 mL, 150 mg/1.5 mL, 300 mg/3 mL
Form: Prefilled autoinjector
Reference Brands: Alhemo (USA/EU)
View Details
Fresh Frozen Plasma (Ffp) Powder For Reconstitution Or Liquid
Strength:
available in 200-250 mL units
Form: liquid units or lyophilized (freeze-dried) powder
Reference Brands: No specific brands
View Details
Plasma Protein Fraction (Ppf) Powder
Strength:
50 mL, 250 mL, or 500 mL
Form: Lyophilized Powder or Liquid
Reference Brands: Plasmanate (US), Octaplas LG, Biotest Plasma (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
